Serious adverse events ‐ mild disease to quiescent (up to 52 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Number of responders · IBD patients
It is very uncertain whether IM erythropoietin changes number of responders ‐ active disease (12 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Serious adverse events · IBD patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of responders ‐ disease activity not stated (12 weeks) · IBD patients
IM erythropoietin + IV iron sucrose showed no clear difference in number of responders ‐ disease activity not stated (12 weeks) compared with IV iron sucrose + IM placebo (low certainty).
1 finding from 1 review
Serious adverse events ‐ disease activity not stated (12 weeks) · IBD patients
1 finding from 1 review
Number of responders · IBD patients
It is very uncertain whether oral ferric maltol changes number of responders ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Treatment success as defined by the authors · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Abdominal pain frequency or change in frequency · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Abdominal pain intensity or change in intensity · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with Crohn's disease
It is very uncertain whether enteric‐release glyceryl trinitrate changes withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Depression response (acute phase, 5 ≤ 12 weeks) · women of any age, with PND up to 12 months
Antidepressants showed no clear difference in depression response (acute, 5 ≤ 12 weeks) compared with placebo (low certainty).
1 finding from 1 review
RR 1.27 [0.97, 1.66]
Studies not reported
Low
Depression remission · women of any age, with PND up to 12 months
Antidepressants showed no clear difference in depression remission (acute, 5 ≤ 12 weeks) compared with placebo (low certainty).
1 finding from 1 review
RR 1.54 [0.99, 2.41]
Studies not reported
Low
Adverse events · women of any age, with PND up to 12 months
Antidepressants may leads to lower adverse events compared with placebo (low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Depression severity (acute phase, 5 ≤ 12 weeks) · women of any age, with PND up to 12 months
2 findings from 1 review
no estimate extracted
Studies not reported
Low
no estimate extracted
Studies not reported
Low
Acceptability ‐ total dropouts · women of any age, with PND up to 12 months
Antidepressants showed no clear difference in treatment acceptability ‐ dropouts compared with placebo (low certainty).
1 finding from 1 review
RR 1.1 [0.74, 1.64]
Studies not reported
Low
Child‐related outcomes · women of any age, with PND up to 12 months
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of dementia · Older people living in the community
Multi‐domain interventions showed no clear difference in incidence of dementia compared with usual care/placebo (high certainty).
1 finding from 1 review
Incidence of MCI · Older people living in the community
Multi‐domain interventions showed no clear difference in incidence of MCI compared with usual care/placebo (moderate certainty).
1 finding from 1 review
Cognitive decline · Older people living in the community
3 findings from 1 review
no estimate extracted
3 studies · 4617 participants
High
no estimate extracted
6 studies · 8697 participants
Moderate
no estimate extracted
2 studies · 1554 participants
Very low
All‐cause mortality · Older people living in the community
Multi‐domain interventions showed no clear difference in mortality compared with usual care/placebo (high certainty).
1 finding from 1 review